Table 3 Fc-glycan distributions (%, average ±  SD) and p-values for group comparisons according to glycan type (i.e. galactosylated: containing galactose [G], agalactosylated: lacking galactose [aG]), afucosylated: lacking fucose [aF], bisected: containing glycan bisection [B], and sialylated: containing sialic acid [S]) for the different subgroups. Additionally the galactosylation status was measured via log(FA2_1/FA2_2), i.e. the intra individual differences of FA2 on IgG1 and IgG2/(3). P-values < 0.005 (5.0E-3, bold numbers) remain significant following FDR correction.

From: Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies

Isotype

Glycan factor

T1

IIM

Jo1−

Jo1+

Jo1+ enrichment

Anti-Jo1

Healthy vs

  

IIM

  

PE

FT

IIM

All T

Jo1−

Jo1+

Jo1−/Jo1+

Anti-Jo1 vs

HC

T1

T1

All T

T1

All T

T1

All T

FT

PE

IgG1/IgG2/(3)

log(FA2_1/FA2_2)

−0.28 ± 0.06

−0.18 ± 0.11

−0.20 ±0.11

−0.15±0.09

−0.16±0.08

−0.18 ± 0.05

−0.09 ± 0.10

1.4E−05

6.1E−06

6.8E−03

1.2E−02

1.8E−06

7.3E−07

6.3E−02

6.3E−02

1.3E−02

9.5E−02

IgG1

Σ[aG_1], n = 5

27 ± 9

37 ± 13

35 ± 13

41 ± 12

41 ± 9

39 ± 4

47 ± 10

1.3E−03

2.3E−04

2.0E−02

2.7E−02

2.2E−04

6.4E−06

1.9E−01

1.2E−01

3.6E−02

2.2E−01

 

Σ[G_1], n = 12

72 ± 9

62 ± 13

64 ± 14

59 ± 12

58 ± 9

60 ± 4

53 ± 10

3.8E−04

2.5E−04

1.9E−02

2.8E−02

1.7E−04

6.8E−06

1.9E−01

1.3E−01

3.7E−02

2.2E−01

 

Σ[S_1], n=5

16 ± 7

13 ± 6

13 ± 6

12 ± 6

10 ± 3

10 ± 4

9 ± 5

3.9E−02

3.1E−02

1.2E−01

5.7E−02

5.6E−02

1.2E−02

4.8E−01

7.4E−01

7.9E−01

6.6E−01

 

Σ[B_1], n = 6

23 ± 6

24 ± 6

25 ± 6

22 ± 6

25 ± 5

24 ± 4

21 ± 6

7.2E−01

5.2E−01

3.4E−01

3.4E−01

5.7E−01

7.8E−01

1.5E−01

2.8E−01

1.0E−02

2.2E−03

 

Σ[aF_1], n = 4

4 ± 2

4 ± 2

5 ± 2

3 ± 2

4 ± 1

4 ± 2

2 ± 2

3.6E−01

2.6E−01

6.7E−02

5.2E−03

4.7E−01

5.1E−01

3.3E−02

3.9E−04

1.7E−03

6.7E−02

IgG2/(3)

Σ[aG_2], n = 5

44 ± 11

48 ± 11

48 ± 10

50 ± 12

51 ± 12

52 ± 8

53 ± 12

1.5E−01

3.5E−02

2.8E−01

2.0E−01

1.6E−01

2.1E−02

5.9E−01

2.7E−01

6.2E−01

3.5E−01

 

Σ[G_2], n = 10

56 ± 11

51 ± 11

52 ± 10

50 ± 12

49 ± 12

47 ± 8

46 ± 12

1.4E−01

3.5E−02

2.7E−01

1.9E−01

1.6E−01

2.1E−02

6.0E−01

2.9E−01

6.2E−01

3.5E−01

 

Σ[S_2], n=5

9 ± 5

8 ± 4

8 ± 4

9 ± 6

8 ± 4

4 ± 3

9 ± 4

4.2E−01

1.8E−01

3.3E−01

2.1E−01

7.0E−01

2.4E−01

7.0E−01

1.0E + 00

6.0E−03

2.6E−01

 

Σ[B_2], n = 6

16 ± 3

16 ± 4

18 ± 3

14 ± 3

15 ± 3

16 ± 3

13 ± 4

9.0E−01

9.7E−01

1.7E−01

1.3E−01

3.4E−02

2.0E−01

9.7E−04

2.0E−03

1.7E−03

3.7E−02

 

Σ[aF_2], n = 2

1 ± 1

1 ± 1

2 ± 1

1 ± 1

1 ± 1

1 ± 1

1 ± 1

5.1E−02

1.5E−02

4.0E−02

1.5E−03

4.4E−01

3.1E−01

3.1E−01

1.1E−02

8.4E−01

9.5E−01

IgG(3)/4

Σ[aG_34], n = 4

45 ± 12

49 ± 12

50 ± 12

47 ± 12

45 ± 9

45 ± 9

48 ± 11

1.7E−01

1.1E−01

1.2E−01

2.3E−02

5.1E−01

5.3E−01

4.5E−01

9.6E−03

1.1E−01

5.1E−02

 

Σ[G_34], n = 7

55 ± 12

51 ± 12

50 ± 12

52 ± 12

55 ± 9

55 ± 9

51 ± 10

1.7E−01

1.2E−01

1.3E−01

2.5E−02

5.0E−01

4.9E−01

4.8E−01

1.0E−02

1.0E−01

3.9E−02

 

Σ[S_34], n = 2

13 ± 6

10 ± 5

10 ± 4

11 ± 6

10 ± 4

9 ± 3

11 ± 4

5.3E−02

7.7E−03

3.7E−02

1.2E−02

2.9E−01

4.6E−02

5.0E−01

1.9E−01

1.8E−01

7.5E−01

 

Σ[B_34], n = 4

25 ± 7

24 ± 6

26 ± 5

21 ± 5

22 ± 6

21 ± 6

27 ± 8

6.6E−01

4.6E−01

4.5E−01

2.2E−01

7.1E−02

2.4E−02

4.9E−03

1.5E−05

4.7E−02

9.5E−03

 

Σ[aF_34], n = 1

0.4 ± 0.4

0.4 ± 0.4

0.4 ± 0.4

0.4 ± 0.5

0.3 ± 0.4

0.3 ± 0.3

0.2 ± 0.2

8.7E−01

6.4E−01

8.0E−01

9.4E−01

9.9E−01

4.1E−01

8.2E−01

2.9E−01

6.6E−01

7.2E−01

IgG (combined)

Σ[aG_total], n = 14

117 ± 30

135 ± 32

133 ± 32

138 ± 33

137 ± 23

137 ± 17

148 ± 26

2.6E−02

6.0E−03

7.0E−02

3.2E−02

4.1E−02

6.5E−03

6.8E−01

9.5E−01

6.3E−02

1.7E−01

 

Σ[G_total], n = 29

183 ± 30

164 ± 32

166 ± 33

161 ± 33

162 ± 23

163 ± 17

151 ± 26

2.5E−02

6.4E−03

6.9E−02

3.3E−02

3.8E−02

6.8E−03

6.6E−01

9.7E−01

5.9E−02

1.6E−01

 

Σ[S_total], n = 12

39 ± 15

31 ± 13

31 ± 11

32 ± 16

28 ± 8

23 ± 9

29 ± 9

4.5E−02

6.8E−03

5.5E−02

1.1E−02

1.6E−01

2.3E−02

9.5E−01

7.3E−01

9.3E−02

8.5E−01

 

Σ[B_total], n = 16

64 ± 13

64 ± 12

68 ± 11

57 ± 12

62 ± 13

61 ± 10

61 ± 15

9.4E−01

9.4E−01

2.2E−01

1.4E−01

9.5E−02

1.8E−01

2.9E−03

2.9E−04

9.5E−01

7.6E−01

 

Σ[aF_total], n = 7

5 ± 2

6 ± 3

7 ± 3

5 ± 3

5 ± 2

6 ± 3

4 ± 2

2.2E−01

2.2E−01

3.6E−02

1.4E−03

7.8E−01

7.5E−01

4.8E−02

1.4E−04

2.1E−02

1.5E−01

  1. Abbreviations: HC: Healthy control, IIM: idiopathic inflammatory myopathies, Jo1−: Jo1 negative, Jo1+: Jo1 positive, PE: IgG Prior Enrichment of anti-Jo1-IgG, FT: Flow Through, anti-Jo1: anti-Jo1 specific IgG, T1: Time point 1, T total: data from all timepoints (T1–T10). Glycan abbreviations are described in Fig. 1. Σ[aG_1]: Σ[IgG1: A2, A2B, FA1, FA2 and FA2B], Σ[G_1]: [IgG1: A2G1, A2G2, FA1G1, FA1G1S1, FA2G1, FA2G2, FA2G1S1, FA2G2S1, FA2BG1, FA2BG2, FA2BG1S1 and FA2BG2S1], Σ[S_1]: [IgG1:FA1G1S1, FA2G1S1, FA2G2S1, FA2BG1S1 and FA2BG2S1], Σ[B_1]: [IgG1: A2B, FA2B, FA2BG1, FA2BG2, FA2BG1S1 and FA2BG2S1], Σ[aF_1]: [IgG1: A2, A2B, A2G1 and A2G2], Σ[aG_2]: [IgG2: A2, A2B, FA1, FA2 and FA2B], Σ[G_2]: [IgG2: FA1G1, FA1G1S1, FA2G1, FA2G2, FA2G1S1, FA2G2S1, FA2BG1, FA2BG2, FA2BG1S1 and FA2BG2S1], Σ[S_2]: [IgG2: FA1G1S1, FA2G1S1, FA2G2S1, FA2BG1S1 and FA2BG2S1], Σ[B_2]: [IgG2: A2B, FA2B, FA2BG1, FA2BG2, FA2BG1S1 and FA2BG2S1], Σ[aF_2]: [IgG2: A2 and A2B], Σ[aG_34]: [IgG34: A2B, FA1, FA2 and FA2B], Σ[G_34]: [IgG34: FA1G1, FA2G1, FA2G2, FA2G1S1, FA2G2S1, FA2BG1 and FA2BG2], Σ[S_34]: [IgG34: FA2G1S1 and FA2G2S1], Σ[B_34]: [IgG34: A2B, FA2B, FA2BG1 and FA2BG2], Σ[aF_34]: [IgG34: A2B], Σ[aG_total]: sum all agalactosylated, Σ[G_total]:sum all galactosylated, Σ[S_total]: sum all sialylated, Σ[B_total]:sum all bistected, Σ[aF_total]:sum all afucosylated. For individual glycan values see Supplementary Table 5.
Back to article page